Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-sample antibody and thrombocytopenia assessment in prior Raptiva-treated psoriasis subjects
2007-001377-28Phase 4Completed
- Sponsor
- Merck Serono
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of efalizumab in plaque psoriasis (2 cohorts), sponsored by Merck Serono. Primary endpoint: Prevalence of binding anti-efalizumab antibodies. Started Feb 2008; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2007-001377-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001377-28.